Sublingual tirzepatide tablets: what the evidence actually says

What does 'sublingual tirzepatide' actually mean, and does it exist?

Sublingual means dissolved under the tongue. It is a legitimate route of administration for some medicines, but tirzepatide has not been developed or approved in that form anywhere in the world, including the UK. The term turns up on social media, in supplement marketing and occasionally on unregulated websites, which is largely where the confusion originates. A common misconception is that pharmaceutical companies are hiding an easier-to-take pill version while continuing to sell injections. They are not. The challenge is biochemical: tirzepatide is a large peptide molecule that enzymes in the gut and mouth degrade before it can reach the bloodstream in useful quantities, which is precisely why the licensed version is injected subcutaneously.

Eli Lilly has not announced a sublingual tirzepatide programme, and our dedicated page explains in more detail why this route of administration has not been developed. What does exist is continued research into alternative delivery methods for GLP-1 class medicines more broadly, but that research has not produced an approved UK product for tirzepatide. The NHS patient information page for tirzepatide describes it as a subcutaneous injection only, which reflects the current licensed reality.

Is there an approved oral tirzepatide tablet in the UK?

Not yet. The MHRA has not approved any oral tirzepatide formulation, sublingual or otherwise, for weight management or any other indication. This is a meaningful distinction because a closely related medicine, semaglutide, did achieve oral approval. In June 2026 the MHRA approved Wegovy tablets as the first oral GLP-1 weight-loss medicine in the UK. That product uses a specific absorption-enhancing technology (SNAC) that helps semaglutide survive digestion long enough to be absorbed from the stomach lining. If you are wondering whether tirzepatide oral tablets could follow a similar path, the science and regulatory picture is covered in full on that page.

If you are interested in what licensed tirzepatide treatment actually involves, the tirzepatide overview on this site covers how the injection works, who it is licensed for and what the clinical trial evidence shows. And if the injection format is the sticking point for you personally, it is worth knowing that many people find the once-weekly Mounjaro KwikPen considerably less daunting than they expected, a point our clinical team hears regularly, and you can read more about Mounjaro tablets if you are curious about what tablet forms of this treatment may involve.

Why do unlicensed sublingual tirzepatide products appear online?

The MHRA has been frank about the scale of the problem. Counterfeit and unlicensed weight-loss medicines circulate through social media, grey-market websites and informal sellers. In 2025 alone, enforcement operations seized roughly 20 million doses of illegally traded weight-loss medicines with an estimated street value of around £45 million, and the first illicit UK site producing counterfeit tirzepatide pens was raided in Northampton. Products labelled as sublingual tirzepatide almost certainly fall into this category: either counterfeit, mislabelled or containing unknown substances. There is no regulatory reference point for what they should contain, because no such product has been assessed. The MHRA's Yellow Card scheme allows anyone to report a suspect seller or an adverse reaction to an unlicensed product.

For context on how to verify any UK online pharmacy before purchasing a prescription medicine, the frequently asked questions page covers what to look for on the GPhC register. You can also read more about licensed weight-loss treatments to understand which medicines are properly authorised in the UK right now.

What are the licensed options if you want to avoid injections?

This is the most practical question for many people searching this term. Right now, the licensed oral GLP-1 option for weight management in the UK is Wegovy tablets (oral semaglutide), approved by the MHRA on 11 June 2026. It is taken once daily, first thing in the morning on an empty stomach, and requires at least 30 minutes before any food or drink. It is a prescription-only medicine, assessed and prescribed after a clinical consultation, and does not require refrigeration. For people whose BMI and medical history makes them eligible, it offers a genuine alternative to injecting.

Tirzepatide, for now, remains an injection. That might change as the science develops, and if Eli Lilly brings an oral formulation through UK regulatory approval, it would be reported through official channels. Until then, any product being sold as sublingual tirzepatide sits outside the licensed supply chain entirely. If you want to explore your options with a prescriber, the free consultation at nume is reviewed the same day by a GPhC-registered prescriber who can talk through which licensed treatment fits your situation. You might also find our pages covering how tirzepatide tablets are being researched and what buying options may look like online in future and the background on the tirzepatide tablet useful reading alongside this page.